"The study published in the Lancet analyzed data from 381 patients with platinum-resistant ovarian cancer, revealing a 35% reduction in the risk of death among those treated with relacorilant compared to usual care."
"Patients in the relacorilant group lived, on average, four months longer than those receiving usual treatment, suggesting a significant improvement in survival rates."
"A separate study involving 643 patients indicated that those treated with pembrolizumab alongside usual care lived for an average of 17.7 months, compared to 14 months for those receiving usual care alone."
Relacorilant, a drug initially used for Cushing's syndrome, shows potential in extending the lives of patients with platinum-resistant ovarian cancer. A clinical trial with 381 patients indicated a 35% reduction in death risk for those treated with relacorilant compared to usual care, with an average survival increase of four months. Another study with 643 patients found that pembrolizumab, an immunotherapy, improved survival to 17.7 months versus 14 months for usual care. Both treatments are in phase 3 trials and require further testing.
Read at www.theguardian.com
Unable to calculate read time
Collection
[
|
...
]